Infigratinib靶向的FGFR3（成纤维细胞生长因子受体3）正是驱动ACH疾病发生的关键靶点，2月12日，BridgeBio公布Infigratinib在ACH中取得的首个具有统计学显著改善意义的3期顶线结果，公司计划下半年向FDA提交新药申请。
Get Deal at Amazon。业内人士推荐51吃瓜作为进阶阅读
"command": "cmdValidatePromo",，这一点在快连下载-Letsvpn下载中也有详细论述
Let our team of writers be your guide to the cricketing world, as they analyse the big stories, revisit the week’s matches and other happenings, and look further afield. Sign up below to start receiving The Spin in your inbox. View the latest edition here.